Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cladribine, Cytarabine, and Decitabine With or Without Venetoclax and Gilteritinib in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Trial Status: active

This phase II trial studies how well cladribine, cytarabine, and decitabine with or without venetoclax and gilteritinib work in treating patients with untreated acute myeloid leukemia, acute myeloid leukemia that has come back after a period of improvement (relapsed), acute myeloid leukemia that does not respond to treatment (refractory) or patients with high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as cladribine, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cladribine, cytarabine, and decitabine with or without venetoclax and gilteritinib may work well in treating patients with untreated, relapsed, or refractory acute myeloid leukemia and patients with high-risk myelodysplastic syndrome.